LncRNA EBIC promoted proliferation, metastasis and cisplatin resistance of ovarian cancer cells and predicted poor survival in ovarian cancer patients

摘要

OBJECTIVE: Ovarian cancer has the highest mortality rate cancer worldwide in women, and it is the second most common gynecologic malignancy in females, but the treatment remained unsatisfactory. Researches showed that lncRNA EBIC had played key roles in different cancer, but its role in ovarian cancer remains largely unclear. PATIENTS AND METHODS: qRT-PCR was applied to detect the expression of lncRNA EBIC in ovarian cancer and adjacent tissue, and analysis was applied to explore the relationship between expression and clinical characteristic. Overall, the survival curves for the two groups were defined by the high and low expression level of EBIC in ovarian cancer patients. After that, CCK8 and transwell were used to detect the proliferation and metastasis ability of ovarian cancer, after suppression of lncRNA EBIC. The relative protein expression level in ovarian cancer cells after transfection with siRNA-NC or siRNA-EIBC was detected by Western blot. RESULTS: qRT-PCR showed that lncRNA EIBC was highly expressed in ovarian cancer tissue, compared with adjacent tissue. Moreover, we found that expression of lncRNA EIBC was closely related to prognosis, tumor size and lymph node metastasis. We also found that the cell proliferation, invasion, migration and cisplatin resistance in ovarian cancer cells after transfection with siRNA-EBIC were significantly inhibited. Mechanistically, the relative protein expression level of β-catenin, vimentin and c-myc were significantly decreased and the relative expression of E-cadherin was significantly increased in ovarian cancer cells after transfection with siRNA-EBIC. CONCLUSIONS: We found that overexpression of lncRNA EBIC could promote the proliferation, invasion and migration and improved cells cisplatin resistance by Wnt/β-catenin signaling pathway in ovarian cancer. LncRNA EBIC may be a potential target for the treatment of ovarian cancer patients.